Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

The University of Texas Health Science Center at San Antonio20 enrolled

Overview

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Aging Diabetes Mellitus, Type 2 PreDiabetes Overweight and Obesity

Interventions

Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.

Lifestyle CounselingBEHAVIORAL

Lifestyle Counseling will be provided throughout study intervention

Eligibility

Sex: ALLMin age: 65 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Older than 65 * Have prediabetes or diabetes * BMI ≥ 27.0 kg/m2 * Living independently (not in assisted living or nursing home) Exclusion Criteria: * Have heart disease * Have liver disease * Smoke

Locations (1)

UT Health San Antonio

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Lean Body Mass Change

Determine if there is any change in lean body mass

Time frame: Baseline to 20 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.